Showing 1461-1470 of 1614 results for "".
- Ocular Therapeutix and AffaMed Therapeutics Announce License Agreement for Dextenza and OTX-TIC in Asiahttps://modernod.com/news/ocular-therapeutix-and-affamed-therapeutics-announce-license-agreement-and-collaboration-for-dextenza-and-otx-tic-in-asia/2478479/Ocular Therapeutix announced a license agreement and a collaboration with AffaMed Therapeutics for the development and commercialization of Dextenza and OTX-TIC in Greater China, South Korea, and the ASEAN markets. Dextenza is currently approved in the U.S. for the treatment of post-surgical ocul
- Samsung Bioepis and Biogen Announce EMA Filing Acceptance of Proposed Lucentis Biosimilarhttps://modernod.com/news/samsung-bioepis-and-biogen-announce-ema-filing-acceptance-of-proposed-lucentis-biosimilar/2478376/Samsung Bioepis and Biogen announced that the European Medicines Agency (EMA) has accepted for review its Marketing Authorization Application for SB11, a proposed biosimilar referencing Lucentis (ranibizumab). Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for retinal vascular d
- Bausch Health Announces Vyzulta Now Approved in Seven Countries; Expanded Coverage in Canadahttps://modernod.com/news/bausch-health-announces-vyzulta-now-approved-in-seven-countries-expanded-coverage-in-canada/2478323/Bausch Health Companies and Nicox announced that Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% has received regulatory approval in Ukraine, bringing the total number of countries where Vyzulta is approved to market to seven. These countries include
- Aerie Pharmaceuticals Announces Interim 90-Day Topline Data From Its 6-Month Mercury 3 Clinical Trial in Europehttps://modernod.com/news/aerie-pharmaceuticals-announces-interim-90-day-topline-data-from-its-6-month-mercury-3-clinical-trial-in-europe/2478321/Aerie Pharmaceuticals announced successful interim 90-day topline data from its 6-month phase 3b clinical trial in Europe known as Mercury 3, comparing Roclanda to Ganfort, according to a company news release. Roclanda is marketed in the United States as Rocklatan (netarsudil and latanopro
- Biomarker Indicating Neurodegeneration Identified in the Eyehttps://modernod.com/news/biomarker-indicating-neurodegeneration-identified-in-the-eye/2478302/A new study led by Boston Medical Center researchers indicates a well-known biomarker that serves as a marker for earlier diagnosis of neurodegenerative diseases is now detectable in the eye. Neurofilament light chain, a protein previously detected in cerebrospinal fluid and blood that is
- MetLife to Acquire Versant Health, Owner of Davis Vision and Superior Visionhttps://modernod.com/news/metlife-to-acquire-versant-health-owner-of-davis-vision-and-superior-vision/2478292/MetLife announced it has entered into a definitive agreement to acquire Versant Health from an investor group led by Centerbridge Partners and including FFL Partners for approximately $1.675 billion in an all-cash transaction. Versant Health owns the marketplace brands Davis Vision and Superior V
- Santen Acquires Eyevance Pharmaceuticalhttps://modernod.com/news/santen-acquires-eyevance-pharmaceutical/2478289/In a move to enter the US pharmaceuticals market and expand its global presence, Santen announced it has acquired Eyevance Pharmaceutical for $225 million in cash. In the deal, Santen Holdings U.S. Inc., a wholly-owned subsidiary of Santen, will acquire all of the outstanding shares of Ey
- Sight Sciences Presents Additional Results of OLYMPIA Study of Signs and Symptoms of Dry Eye Disease Using TearCarehttps://modernod.com/news/sight-sciences-presents-additional-results-of-olympia-study-of-signs-and-symptoms-of-dry-eye-disease-using-tearcare/2478263/Sight Sciences announced further favorable results of a trial evaluating a single treatment of TearCare for the treatment of signs and symptoms of dry eye disease in patients with meibomian gland dysfunction. TearCare is currently marketed for the application of localized heat to the eyelids for
- Health Canada Authorizes Enspryng for Canadians Living with Neuromyelitis Optica Spectrum Disorderhttps://modernod.com/news/health-canada-authorizes-enspryng-for-canadians-living-with-neuromyelitis-optica-spectrum-disorder/2478219/Roche Canada announced that Health Canada has granted market authorization for Enspryng (satralizumab) as monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult and adolescent patients who are anti-aqu
- Topcon Announces the US Launch of Aladdin-Mhttps://modernod.com/news/topcon-announces-the-us-launch-of-aladdin-m/2478217/Topcon Healthcare announced that it has launched its new Aladdin-M instrument in the US market. Aladdin-M combines corneal topography, pupillometry, and optical biometry to enable objective measurement of corneal curvature, pupil dynamics, and axial length metrics. The all-in-one Aladdin-M